Home › Categories › Health & Wellness› Prescribing Information

Prescribing Information.pdf

zilbrysq-prescribing-information.pdf

🔗 Source: ucb-usa.com

📊 Size: 1.11 MB

👤 Author: Rigobello Chiara

⬇️ Downloads: 102

Summary

ZILBRYSQ (zilucoplan) is a complement inhibitor for subcutaneous use, initially approved in the US in 2023. It increases the risk of serious meningococcal infections, and patients should be vaccinated against meningococcal bacteria at least 2 weeks prior to the first dose. ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. The recommended dosage is once daily, dependent on actual body weight, with dosages of 16.6 mg, 23 mg, or 32.4 mg. Common adverse reactions include injection site reactions, upper respiratory tract infection, and diarrhea. ZILBRYSQ is available only through a restricted program called ZILBRYSQ REMS due to the risk of serious meningococcal infections.

Download File

Description

ZILBRYSQ (zilucoplan) is a complement inhibitor for subcutaneous use, initially approved in the US in 2023.

Technical Information

File Format: PDF
File Size: 1.11 MB
Pages: 30
Language: EN
Author: Rigobello Chiara
Total Downloads: 102
Last Updated: 2 weeks ago

Document Overview

This PDF document about Prescribing Information provides comprehensive information and guidance. Whether you're a beginner or advanced user, this resource offers valuable insights into Prescribing Information.